03 August 2012 09:51

Knight Capital fingers tech glitch for stock market chaos; faces $440m pre-tax loss

 

Knight Capital issued a statement that a "technology issue" at its market making unit was behind the volatile price movements in 140 shares yesterday that forced Nyse Euronext to cancel trades.

In early morning trading prices in dozens of stocks went haywire, reviving memories of the May 210 flash crash. After reviewing 140 stocks, Nyse Euronext eventually cancelled orders in six.

With the finger of blame pointing at it and a faulty algorithm, Knight Capital confirmed that it was behind the chaos, saying: "This morning, a technology issue occurred in Knight's market-making unit related to the routing of shares of approximately 150 stocks to the Nyse."

The Securities and Exchange Commission has confirmed it will be looking at the issue, saying: "As is our practice, we are closely monitoring the situation and in continuous contact with the Nyse and other market participants."

Shares in Knight - which, according to Bloomberg, helped execute almost $20 billion of equity transactions a day in June - closed yesterday just shy of 33% down, at $6.94.

In a statement on Thursday, Knight says: "As previously disclosed, Knight experienced a technology issue at the open of trading at the Nyse yesterday, August 1st. This issue was related to Knight's installation of trading software and resulted in Knight sending numerous erroneous orders in Nyse-listed securities into the market. This software has been removed from the company's systems.

"Clients were not negatively affected by the erroneous orders, and the software issue was limited to the routing of certain listed stocks to Nyse.

"Knight has traded out of its entire erroneous trade position, which has resulted in a realized pre-tax loss of approximately $440 million. Although the company's capital base has been severely impacted, the company's broker/dealer subsidiaries are in full compliance with their net capital requirements. Knight will continue its trading and market making activities at the commencement of trading today. The company is actively pursuing its strategic and financing alternatives to strengthen its capital base."

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
24 Aug
FING-B
Sig mig.. har du slet ingen skam i livet !!.. du stjæler ENDNU ENGANG et skriv fra en anden skribent..
22
23 Aug
BAVA
Bavarian Nordic har sammen med Crucell og div. myndigheder igangsat to interessante nye forsøg med M..
18
20 Aug
MAERSK-B
Jeg har gravet mig ind i 6-8 oil projekter, der vil tjene Maersk Oil fra 2016 og frem, og Johan Sver..
17
24 Aug
ZEAL
I Solothum uden for Bern i Svejts ligger en fabrik, hvor der er blevet investeret 50 mio CHF det sen..
16
23 Aug
 
http://borsen.dk/nyheder/politik/artikel/1/330221/opgoerelse_viser_nye_milliarder_tabt_til_skattesvi..
15
21 Aug
ZEAL
Bølgerne har gået højt her på EI’s forum siden Sanofi fredag oplyst at et mere endeligt svar på sags..
15
23 Aug
DANSKE
Tro ikke på 6212 han er blot en bondeknold, der efterhånden er gået kold arme stakkels lille trold, ..
14
19 Aug
GEN
jeg HAR selv Genmab - så er det på plads.   -------------------   Ganske kort mener jeg noget i stil..
13
24 Aug
GEN
Patientgrundlaget er vurderet til at være ca. 20.000 patienter i US plus de 5 største lande i EU for..
12
18:04
GEN
Stop nu det mobberi GW   Jeg elsker at følge den aktie, og det er så trist at du altid skal hævde di..
11

Form 8.3 - Anheuser-Busch InBev SA/NV

25/08/2016 15:25:06
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Alliance Trust PLC : Net Asset Value(s)

25/08/2016 13:24:48
ALLIANCE TRUST PLC                                    At the close of business on Wednesday 24 August 2016: The Company's NAV per ordinary sha..

OZ Management LP : Form 8.3 - J Sainsbury Plc

25/08/2016 10:47:42
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
FIT Biotech Oy: FIT Biotech's GMP facility audited and approved - the company resumes manufacturing of drug candidates
2
Maurel & Prom : Completion of the acquisition by Pertamina of the entire shareholding held by Pacifico in Maurel & Prom
3
Half Yearly Report for the Six Months ended 30 June 2016
4
Data from Phase III CASTOR Study of Daratumumab Published in The New England Journal of Medicine
5
Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2016   Disclaimer and Terms of Use
Quote information is delivered by Interactive Data.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
25 August 2016 22:54:15
(UTC) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20160823.1 - EUROWEB6 - 2016-08-25 23:54:15 - 2016-08-25 22:54:15 - 1000 - Website: OKAY